Nilotinib hampers the proliferation and function of CD8<sup>+</sup> T lymphocytes through inhibition of T cell receptor signalling

J. Chen(Universität Ulm), Michael Schmitt(German Cancer Research Center)

Journal of Cellular and Molecular Medicine

October 1, 2008

10.1111/j.1582-4934.2008.00234.x

Cited by 78

Related Papers

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

|Nature Medicine|2023|226

Effects of nilotinib on regulatory T cells: the dose matters

|Molecular Cancer|2010|29

ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS

|Neuro-Oncology|2018|26

Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses

|Theranostics|2017|11

Peptide Vaccination Against Cytomegalovirus (CMV) Elicits Immunological and Clinical Responses after Allogeneic Stem Cell Transplantation Even from a CMV Seronegative Donor

|Blood|2016|1